JP2018535199A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535199A5
JP2018535199A5 JP2018517807A JP2018517807A JP2018535199A5 JP 2018535199 A5 JP2018535199 A5 JP 2018535199A5 JP 2018517807 A JP2018517807 A JP 2018517807A JP 2018517807 A JP2018517807 A JP 2018517807A JP 2018535199 A5 JP2018535199 A5 JP 2018535199A5
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
hydrogen
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517807A
Other languages
English (en)
Japanese (ja)
Other versions
JP6912460B2 (ja
JP2018535199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/073962 external-priority patent/WO2017060406A1/en
Publication of JP2018535199A publication Critical patent/JP2018535199A/ja
Publication of JP2018535199A5 publication Critical patent/JP2018535199A5/ja
Application granted granted Critical
Publication of JP6912460B2 publication Critical patent/JP6912460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517807A 2015-10-09 2016-10-07 PI3Kβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体 Active JP6912460B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15189163 2015-10-09
EP15189163.7 2015-10-09
EP16174710.0 2016-06-16
EP16174710 2016-06-16
PCT/EP2016/073962 WO2017060406A1 (en) 2015-10-09 2016-10-07 Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors

Publications (3)

Publication Number Publication Date
JP2018535199A JP2018535199A (ja) 2018-11-29
JP2018535199A5 true JP2018535199A5 (https=) 2019-11-07
JP6912460B2 JP6912460B2 (ja) 2021-08-04

Family

ID=57104028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517807A Active JP6912460B2 (ja) 2015-10-09 2016-10-07 PI3Kβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体

Country Status (14)

Country Link
US (2) US10526316B2 (https=)
EP (1) EP3359533B1 (https=)
JP (1) JP6912460B2 (https=)
KR (1) KR102630111B1 (https=)
CN (1) CN108349946B (https=)
AU (1) AU2016335086B2 (https=)
BR (1) BR112018007068B1 (https=)
CA (1) CA2999818C (https=)
EA (1) EA037401B1 (https=)
ES (1) ES2905673T3 (https=)
IL (1) IL258513B (https=)
MA (1) MA45896A (https=)
MX (1) MX382601B (https=)
WO (1) WO2017060406A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526316B2 (en) 2015-10-09 2020-01-07 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
DK3472160T3 (da) 2016-06-16 2021-05-10 Janssen Pharmaceutica Nv Bicykliske pyridin-, pyrazin- og pyrimidinderivater som pi3k-beta-inhibitorer
EP3601254B1 (en) * 2017-03-29 2022-05-25 Janssen Pharmaceutica NV Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN111892597B (zh) * 2020-09-01 2023-07-25 山西天宏达安医药科技有限公司 一种喹喔啉基吡啶并吡嗪类化合物及其制备方法与应用
WO2024026419A1 (en) * 2022-07-27 2024-02-01 Black Diamond Therapeutics, Inc. Quinoxaline derivatives as pik3 alpha modulators
AU2024272375A1 (en) * 2023-05-12 2026-01-08 Mirati Therapeutics, Inc. Substituted quinoxalines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1993537A4 (en) 2006-03-02 2010-05-19 Glaxosmithkline Llc THIAZOLONES AS INHIBITORS OF P13-KINASES
WO2008014219A2 (en) 2006-07-24 2008-01-31 Smithkline Beecham Corporation Thiozolidinedione derivatives as p13 kinase inhibitors
NZ578229A (en) * 2007-02-22 2012-02-24 Merck Serono Sa Quinoxaline compounds and use thereof
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
KR20120081164A (ko) 2009-09-29 2012-07-18 엑스커버리 홀딩 컴퍼니 엘엘씨 Pi3k(델타) 선택적 억제제
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
JP5719028B2 (ja) 2010-10-06 2015-05-13 グラクソスミスクライン エルエルシー Pi3キナーゼ阻害剤としてのベンズイミダゾール誘導体
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
WO2013095761A1 (en) 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
AU2015366202B2 (en) 2014-12-19 2020-01-02 Janssen Pharmaceutica Nv Heterocyclyl linked imidazopyridazine derivatives as PI3Kbeta inhibitors
MA41174B1 (fr) 2014-12-19 2019-09-30 Janssen Pharmaceutica Nv Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
US10526316B2 (en) 2015-10-09 2020-01-07 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors

Similar Documents

Publication Publication Date Title
JP2018535199A5 (https=)
JP2019518059A5 (https=)
JP2018528946A5 (https=)
JP2015514808A5 (https=)
JP2016530259A5 (https=)
JP2013529611A5 (https=)
JP2019509276A5 (https=)
JP2013523614A5 (https=)
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
SG11201809859VA (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
JP2016505512A5 (https=)
JP2015504081A5 (https=)
JP2013510124A5 (https=)
MX382192B (es) Composiciones de canabinoide y usos.
EP4696380A3 (en) Benzoxazepin oxazolidinone compounds and methods of use
CL2013003647A1 (es) Compuestos derivados de pirrolo[2,3-d] pirimidina o pirrolo[2,3-b]piridina, inhibidores de la actividad de jak; composicion farmaceutica; utiles para el tratamiento de enfermedades autoinmunitarias, inflamatorias y de reabsorcion osea, cancer, trastornos mieloproliferativos o rechazo a trasplante de organos.
JP2010523522A5 (https=)
ME02181B (me) Ne-nukleozidni inhibitori reverzne transkriptaze
JP2014511892A5 (https=)
JP2014513110A5 (https=)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2020500866A5 (https=)
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
JP2017517565A5 (https=)